Table 3.
The utilization of different medications between the two groups.
| Medication | Group A: stage 2 (N = 31) | Group B: stage 3 (N = 29) | P values1 | ||
|---|---|---|---|---|---|
| n (%) | Mean ± SD | n (%) | Mean ± SD | ||
| Bisphosphonates | |||||
| Zoledronic acid | 25 (80.6) | 35.0 ± 20.3 | 28 (96.9) | 29.3 ± 18.2 | 0.285 |
| Alendronate | 6 (19.4) | 75.0 ± 38.0 | 1 (3.1) | 90.0 | 0.104 |
| Routes | |||||
| IV | 25 (80.6) | 28 (96.9) | |||
| Oral | 6 (19.4) | 1 (3.1) | |||
| Chemotherapy | |||||
| Paclitaxel | 0 | 0 | 3 (7.1) | 7.3 ± 4.2 | |
| Cisplatin | 5 (27.7) | 6.2 ± 1.5 | 11 (26.2) | 11.2 ± 7.3 | |
| Pemetrexed | 6 (33.3) | 5.5 ± 1.4 | 11 (26.2) | 11.5 ± 7.2 | |
| Tegafur/gimeracil/oteracil | 2 (11.1) | 10.0 ± 2.0 | 2 (4.8) | 21.5 ± 20.5 | |
| Gemcitabine | 0 | 0 | 1 (2.4) | 25.0 | |
| Nedaplatin | 1 (5.6) | 5 | 0 | 0 | |
| Cyclophosphamide (IV) | 0 | 0 | 2 (4.8) | 4.5 ± 0.5 | |
| Cyclophosphamide (O) | 1 (5.6) | 24.0 | 2 (4.8) | 25.0 ± 15.6 | |
| Vindesine | 0 | 0 | 3 (7.1) | 5.3 ± 0.8 | |
| Docetaxel | 1 (5.6) | 6.0 | 4 (9.5) | 9.6 ± 2.3 | |
| Bortezomib | 2 (11.1) | 67.5 ± 9.5 | 3 (7.1) | 16.3 ± 2.6 | |
| 2Count | 11 (35.4) | 16.3 ± 21.4 | 21 (72.4) | 14.6 ± 9.7 | 0.771 |
| Targeted drugs | |||||
| Apatinib | 3 (23.0) | 19.0 ± 16.0 | 1 (4.5) | 15.0 | |
| Rituximab (time) | 0 | 0 | 2 (9.2) | 9.5 ± 7.5 | |
| Erlotinib | 1 (7.7) | 50.0 | 0 | 0 | |
| Icotinib | 3 (23.1) | 30.0 ± 6.5 | 2 (9.2) | 28.0 ± 7.0 | |
| Bevacizumab | 1 (7.7) | 24.0 | 2 (9.2) | 22.0 ± 10.0 | |
| Gefitinib | 3 (23.1) | 10.0 ± 2.0 | 5 (22.7) | 40.3 ± 25.7 | |
| Osimertinib | 1 (7.7) | 6.0 | 3 (13.6) | 12.0 ± 3.0 | |
| Sunitinib | 0 | 0 | 3 (13.6) | 45.7 ± 12 | |
| Anlotinib | 0 | 0 | 1 (4.5) | 3.0 | |
| Pazopanib | 0 | 0 | 1 (4.5) | 8.0 | |
| Axitinib | 0 | 0 | 1 (4.5) | 5.0 | |
| Sorafenib | 0 | 0 | 1 (4.5) | 72.0 | |
| Afatinib | 1 (7.7) | 3.0 | 0 | 0 | |
| 2Count | 7 (22.6) | 37.9 ± 18.5 | 16 (55.2) | 32.9 ± 23.4 | 0.629 |
| Immunosuppressive drugs | |||||
| Thalidomide | 2 (40.0) | 66.0 + 42.0 | 3 (27.2) | 23.3 ± 9.29 | |
| GCs | 2 (40.0) | NA | 7 (63.6) | NA | |
| Anti-PD-1 | 1 (20.0) | 1.0 | 1 (9.0) | 3.0 | |
1 P values of medication duration or time were calculated. 2Count: the total number of patients administered with chemotherapy or targeted drugs and the total time or duration of these medications in the two groups were counted. ∗P values were statistically significant. The percentage of 2count (%) was the total number of patients receiving chemotherapy or targeted drugs divided by the total number of patients in different groups. SD: standard deviation; NA: not applicable.